Characterization of serogroup A Neisseria meningitidis from invasive meningococcal disease cases in Canada between 1979 and 2006: Epidemiological links to returning travellers

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 19, Issue 3, 2008, Pages 227-232

  Sloan, Angela M ^a   Henderson, Averil M ^b   Tsang, Raymond S W ^a,b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Canada; Invasive meningococcal disease; Neisseria meningitides; Serogroup A

Indexed keywords

MEMBRANE ANTIGEN;

ALLELE; AMINO ACID SEQUENCE; ARTICLE; BACTERIUM ISOLATION; CANADA; CLINICAL ARTICLE; HUMAN; MENINGOCOCCOSIS; MOLECULAR CLONING; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; SEROLOGY; SEROTYPING; TRAVEL;

EID: 49149105605     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/523021     Document Type: Article

References (46)

1. DeVoe IW. The meningococcus and mechanisms of pathogenicity. Microbiol Rev 1982;46:162-90.
2. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001;344:1378-88.
3. Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004;23:S274-9.
4. Mackinnon FG, Borrow R, Gorringe AR, Fox AJ, Jones DM, Robinson A. Demonstration of lipooligosaccharide immunotype and capsule as virulence factors for Neisseria meningitidis using an infant mouse intranasal infection model. Microb Pathog 1993;15:359-66.
5. Unkmeir A, Kämmerer U, Stade A, et al. Lipooligosaccharide and polysaccharide capsule: Virulence factors of Neisseria meningitidis that determine meningococcal interaction with human dendritic cells. Infect Immun 2002;70:2454-62.
6. Jennings HJ. Capsular polysaccharides as vaccine candidates. Curr Top Microbiol Immunol 1990;150:97-127.
7. Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54:1-21.
8. Cartwright K, Noah N, Peltola H; Meningococcal Disease Advisory Board. Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000. Vaccine 2001;19:4347-56.
9. Public Health Agency of Canada. Guidelines for the prevention and control of meningococcal disease. Can Commun Dis Rep 2005;31S1:1-21.
10. Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999;93:341-53.
11. World Health Organization. Meningococcal meningitis. World Health Organization . 2007. 〈http://www.who.int/mediacentre/factsheets/fs141/en/ 〉 (Version current at March 11, 2008).
12. Achtman M. Epidemic spread and antigenic variability of Neisseria meningitidis. Trends Microbiol 1995;3:186-92.
13. Wang JF, Caugant DA, Li X, et al. Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infect Immun 1992;60:5267-82. (Erratum in Infect Immun 1994;62:5706).
14. Frasch CE, Zollinger WD, Poolman JT Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 1985;7:504-10.
15. Scholten RJ, Bijlmer HA, Poolman JT, et al. Meningococcal disease in The Netherlands, 1958-1990: A steady increase in the incidence since 1982 parrially caused by new serotypes and subtypes of Neisseria meningitidis. Clin Infect Dis 1993;16:237-46.
16. Tsai CM, Frasch CE, Mocca LF. Five structural classes of major outer membrane proteins in Neisseria meningitidis. J Bacteriol 1981;146:69-78.
17. van der Ley P, Heckels JE, Virji M, Hoogerhout P, Poolman JT. Topology of outer membrane porins in pathogenic Neisseria spp Infect Immun 1991;59:2963-71.
18. Sacchi CT, Lemos AP, Whitney AM, et al. Correlation between serological and sequencing analyses of the PorB outer membrane protein in the Neisseria meningitidis serotyping system. Clin Diagn Lab Immunol 1998;5:348-54.
19. Barlow AK, Heckels JE, Clarke IN. The class 1 outer membrane protein of Neisseria meningitidis: Gene sequence and structural and immunological similarities to gonococcal porins. Mol Microbiol 1989;3:131-9.
20. Clarke SC, Diggle MA, Mölling P, Unemo M, Olcén P. Analysis of PorA variable region 3 in meningococci: Implications for vaccine policy? Vaccine 2003;21:2468-73.
21. Sacchi CT, Lemos AP, Brandt ME, et al. Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. Clin Diagn Lab Immunol 1998;5:845-55.
22. Black JR, Dyer DW, Thompson MK, Sparling PF. Human immune response to iron-repressible outer membrane proteins of Neisseria meningitidis. Infect Immun 1986;54:710-3.
23. Thompson EA, Feavers IM, Maiden MC. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 2003;149:1849-58.
24. Olyhoek T, Crowe BA, Achtman M. Clonal population structure of Neisseria meningitidis serogroup A isolated from epidemics and pandemics between 1915 and 1983. Rev Infect Dis 1987;9:665-92.
25. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998;95:3140-5.
26. Jolley KA, Chan MS, Maiden MC. mlstdbNet - distributed multi-locus sequence typing (MLST) databases. BMC Bioinformatics 2004;5:86.
27. Caugant DA. Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 1998;106:505-25.
28. Yazdankhah SP, Kriz P, Tzanakaki G, et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 2004;42:5146-53.
29. Yazdankhah SP, Caugant DA. Neisseria meningitidis: An overview of the carriage state. J Med Microbiol 2004;53:821-32.
30. Peltola H. Meningococcal disease: Still with us. Rev Infect Dis 1983;5:71-91.
31. Caugant DA, Mocca LF, Frasch CE, Frøholm LO, Zollinger WD, Selander RK. Genetic structure of Neisseria meningitidis populations in relation to serogroup, serotype, and outer membrane protein pattern. J Bacteriol 1987;169:2781-92.
32. Liu TY, Gotschlich EC, Jonssen EK, Wysocki JR. Studies on the meningococcal polysaccharides. 1. Composition and chemical properties of the group A polysaccharide. J Biol Chem 1971;246:2849-58.
33. Ashton FE, Ryan A, Diena BB, Frasch CE. Evaluation of the antiserum agar method for the serogroup identification of Neisseria meningitidis. Can J Microbiol 1979;25:784-7.
34. Riou JY, Guibourdenche M. Laboratory methods: Neisseria and Branhamella. Paris: Institut Pasteur, 1992.
35. Matsika-Claquin MD, Perrocheau A, Taha MK, et al. [Meningococcal W135 infection epidemics associated with pilgrimage to Mecca in 2000]. Presse Med 2001;30:1529-34.
36. Abdillahi H, Poolman JT. Whole cell ELISA for typing Neisseria meningitidis with monoclonal antibodies. FEMS Microbiol Lett 2007;48:367-71.
37. Urwin R, Russell JE, Thompson EA, et al. Distribution of surface prorein variants among hyperinvasive meningococci: Implications for vaccine design. Infect Immun 2004;72:5955-62.
38. Moore PS, Reeves MW, Schwartz B, Gellin BG, Broome CV Intercontinental spread of an epidemic group A Neisseria meningitidis strain. Lancet 1989;2:260-3.
39. Achtman M, van der EA, Zhu P et al. Molecular epidemiology of serogroup A meningitis in Moscow, 1969 to 1997. Emerg Infect Dis 2001;7:420-7.
40. Nicolas P, Décousset L, Riglet V, Castelli P, Stor R, Blanchet G. Clonal expansion of sequence type (ST-)5 and emergence of ST-7 in serogroup A meningococci, Africa. Emerg Infect Dis 2001;7:849-54.
41. World Health Organization. Meningococcal disease in India. 〈http://www.who.int/csr/don/2005_05_09/en/index.html〉 (Version current at March 11, 2008).
42. Squires SG, Deeks SL, Tsang RS. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 1999, through 31 December, 2001. Can Commun Dis Rep 2004;30:17-28.
43. Manchanda V, Bhalla P. Emergence of non-ceftriaxone-susceptible Neisseria meningitidis in India. J Clin Microbiol 2006;44:4290-1.
44. Mehta G, Goyal R. Emerging fluoroquinolone resistance in Neisseria meningitidis in India: Cause for concern. J Antimicrob Chemorher 2007;59:329-30.
45. World Health Organization. Risk of epidemic meningitis in Africa: A cause for concern. Wkly Epidemiol Rec 2007;82:79-87.
46. Suker J, Feavers IM, Maiden MC. Monoclonal antibody recognition of members of the meningococcal P1.10 variable region family: Implications for serological typing and vaccine design. Microbiology 1996;142(Pt 1):63-9.